Guggenheim Capital LLC Takes Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Guggenheim Capital LLC acquired a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 23,797 shares of the biopharmaceutical company's stock, valued at approximately $601,000.

Several other large investors also recently bought and sold shares of the business. Barclays PLC increased its stake in shares of Celldex Therapeutics by 140.7% in the 3rd quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company's stock worth $4,431,000 after acquiring an additional 76,207 shares during the last quarter. Mirador Capital Partners LP increased its position in Celldex Therapeutics by 2.9% during the fourth quarter. Mirador Capital Partners LP now owns 119,492 shares of the biopharmaceutical company's stock worth $3,020,000 after purchasing an additional 3,345 shares during the last quarter. SG Americas Securities LLC raised its stake in Celldex Therapeutics by 24.4% during the fourth quarter. SG Americas Securities LLC now owns 25,283 shares of the biopharmaceutical company's stock worth $639,000 after purchasing an additional 4,967 shares during the period. KBC Group NV raised its stake in Celldex Therapeutics by 79.1% during the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after purchasing an additional 1,647 shares during the period. Finally, Sovran Advisors LLC acquired a new position in Celldex Therapeutics in the 4th quarter valued at about $2,867,000.

Analyst Ratings Changes

CLDX has been the subject of a number of recent analyst reports. Cantor Fitzgerald restated an "overweight" rating and set a $67.00 price target on shares of Celldex Therapeutics in a report on Wednesday, January 29th. UBS Group assumed coverage on Celldex Therapeutics in a research note on Thursday, February 13th. They set a "buy" rating and a $44.00 target price for the company. Morgan Stanley started coverage on Celldex Therapeutics in a research note on Thursday, March 20th. They issued an "overweight" rating and a $46.00 price target on the stock. The Goldman Sachs Group cut their price objective on Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a research report on Monday, March 3rd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research report on Friday, February 28th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $55.30.

Celldex Therapeutics Price Performance

Shares of NASDAQ CLDX traded down $0.56 during midday trading on Thursday, hitting $20.28. The company's stock had a trading volume of 117,391 shares, compared to its average volume of 881,844. The firm has a market capitalization of $1.35 billion, a price-to-earnings ratio of -7.90 and a beta of 1.59. Celldex Therapeutics, Inc. has a 1 year low of $14.40 and a 1 year high of $47.00. The business's fifty day simple moving average is $19.11 and its two-hundred day simple moving average is $23.34.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping analysts' consensus estimates of ($0.73) by $0.02. The business had revenue of $1.18 million for the quarter, compared to analyst estimates of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. Analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.